Figure 4
From: Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv
In vivo angiogenesis inhibition by L1, L2 and bevacizumab. (A) Lateral view of subintestinal vessels (SIVs) in fli1:EGFP transgenic zebrafish larvae at 3 dpf. (B) PBS (negative control) (C) 27.5 μM bevacizumab (D) 55 μM L1, (E) 55 μM L2 were injected into yolk of 2 dpf fli1:EGFP transgenic zebrafish embryos. At 3 dpf, zebrafish SIVs were imaged by confocal microscopy. (F) Percentages of average SIV areas were quantified. The outcomes are expressed as AVG ± SD. nPBS = 25, nbevacizumab = 24, nL1 = 24, nL2 = 23. Statistical analysis was performed using one-tail t-test. Statistical results: n.s. p > 0.05, ****p < 0.0001.
